DOI QR코드

DOI QR Code

Pharmacokinetic Analysis of Montelukast in Healthy Korean Volunteers by High Performance Liquid Chromatography-Tandem Mass Spectrometry

  • Received : 2011.07.27
  • Accepted : 2011.08.08
  • Published : 2011.10.20

Abstract

A rapid and specific high performance liquid chromatography-tandem mass (LC/MS/MS) method for the analysis of montelukast in human plasma has been developed and validated. After cold acetonitrile-induced precipitation of the plasma samples, montelukast and glipizide (internal standard, IS) were eluted on a reverse-phase $C_{18}$ column by isocratic mobile phase consisted of 10 mM ammonium formate buffer (adjusted to pH 3.5 with formic acid) and acetonitrile (3:97, v/v). Acquisition was performed with multiple reaction monitoring (MRM) mode by monitoring the transitions: m/z 587.2${\rightarrow}$ 423.2 for montelukast and m/z 446.0${\rightarrow}$321.2 for IS. Ranges of concentration for calibration curves (10-1000 ng/mL) showed correlation coefficients ($r^2$) were better than 0.9948. Precision of intra- and inter-day ranged from 3.70 to 11.68% and from 3.04 to 12.95%, accuracy of intra-day and inter-day ranged from 93.34 to 102.75% and from 100.79 to 107.63%, respectively. The described method provides a fast and sensitive analytical tool for determining montelukast levels in plasma, and was successfully applied to a pharmacokinetic study in 16 healthy human subjects after oral administration of 10mg tablet formulation of montelukast sodium under fasting conditions.

Keywords

References

  1. Challa, B.R., Awen B.Z., Chandu, B.R., Khagga, M., Kotthapalli, CB., 2010. Method development and validation of montelukast in human plasma by HPLC coupled with ESI-MS/ MS: Application to a bioequivalence study. Sci Pharm. 78(3), 411-422. https://doi.org/10.3797/scipharm.1002-07
  2. Sripalakit, P., Kongthong, B., Saraphanchotiwitthaya, A., 2008. A simple bioanalytical assay for determination of montelukast in human plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 869(1-2), 38-44. https://doi.org/10.1016/j.jchromb.2008.05.017
  3. Mastalerz, L., Kumik, J., 2010. Antileukotriene drugs in the treatment of asthma. Pol Arch Med Wewn. 120(3), 103-108.
  4. Castro-Rodriguez, J.A., Rodrigo, G.J., 2010. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis. Arch Dis Child. 95(5), 365-370. https://doi.org/10.1136/adc.2009.169177
  5. Yasar, H., Kiran, B., Cagatay, T., Ozkul, H., Icten, S., 2011. The effect of montelukast sodium on serum arginase levels in patients with seasonal allergic rhinitis. Am J Rhinol Allergy.
  6. Schaper, C., Noga, O., Koch, B., Ewert, R., Felix, S.B., Gläser S., Kunkel, G., Gustavus B., 2011. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol. 21(1), 51-58.
  7. Amin, R.D., Cheng, H., Rogers, J.D., 1995. Determination of MK- 0476 in human plasma by liquid chromatography. J Pharm Biomed Anal. 13(2), 155-158. https://doi.org/10.1016/0731-7085(94)00138-R
  8. Liu, L., Cheng, H., Zhao, J.J., Rogers, J.D., 1997. Determination of montelukast (MK-0476) and its S-enantiomer in human plasma by stereoselective high-performance liquid chromatography with column-switching. J Pharm Biomed Anal. 15(5), 631-638. https://doi.org/10.1016/S0731-7085(96)01894-8
  9. Al-Rawithi, S., Al-Gazlan, S., Al-Ahmadi, W., Alshowaier, IA., Yusuf, A., Raines, D.A., 2011. Expedient liquid chromatographic method with fluorescence detection for montelukast sodium in micro-samples of plasma. J Chromatogr B Biomed Sci. 754(2), 527-531.
  10. Smith, G.A., Rawls, C.M., Kunka, R.L., 2004. An automated method for the determination of montelukast in human plasma using dual-column HPLC analysis and peak height summation of the parent compound and its photodegradation product. Pharm Res. 21(9), 1539-1544. https://doi.org/10.1023/B:PHAM.0000041445.76931.27
  11. Bharathi, D.V., Hotha, K.K., Jagadeesh, B., Mullangi, R., Naidu, A., 2009. Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. Biomed Chromatogr. 23(8), 804-810. https://doi.org/10.1002/bmc.1189
  12. Cheng, H., Leff, J.A., Amin, R., Gertz, B.J., De Smet, M., Noonan, N., Rogers, J.D., Malbecq, W., Meisner, D. Somers, G., 1996. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharmaceutical Research. 13, 445-448. https://doi.org/10.1023/A:1016056912698
  13. Ochiai, H., Uchiyama, N., Takano, T., Hara, K., Kamei, T., 1998. Determination of montelukast sodium in human plasma by column-switching high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl. 713(2), 409-414. https://doi.org/10.1016/S0378-4347(98)00179-0
  14. Alsarra, I., Khalil, NY., Sultan, M., Al-Ashban, R., Belal, F., 2005. Spectrofluorometric determination of montelukast in dosage forms and spiked human plasma. Pharmazie. 60(11), 823-826.
  15. Al Omari, M.M., Zoubi, R.M., Hasan, E.I., Khader, T.Z., Badwan, A.A., 2007. Effect of light and heat on the stability of montelukast in solution and in its solid state. J Pharm Biomed Anal. 45(3), 465-471. https://doi.org/10.1016/j.jpba.2007.07.014
  16. Korea FDA, 2003 Guideline for the Validation of Bioanalytical Method 2003.05.